VSIR and neoplasm: With VISTA maintaining a large percent of T cells in a quiescent state, anti-VISTA will bring these cells out of quiescence and lower their threshold for tumor antigen recognition, further enhancing T-cell effector function of antigen presentation on APCs promoted by anti-PD-1/PD-L1.